Back to top
more

Helius Medical Technologies (HSDT)

(Delayed Data from NSDQ)

$4.50 USD

4.50
5,069

+0.06 (1.35%)

Updated Apr 26, 2024 03:37 PM ET

After-Market: $4.66 +0.16 (3.56%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know

The mean of analysts' price targets for Helius Medical Technologies, Inc. (HSDT) points to a 1249.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Helius Medical Technologies, Inc. (HSDT)? Wall Street Analysts Think 1183.3%

The consensus price target hints at an 1183.3% upside potential for Helius Medical Technologies, Inc. (HSDT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 45.45% and 50.59%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Surpasses Q2 Earnings Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 19.64% and 2.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.54% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q1 Loss, Lags Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.26% and 1.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Reports Q1 Loss, Lags Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of 18.18% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

5 Winning Stocks Backed by the Overlooked Rising P/E Trick

Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).

Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Q3 Earnings and Revenues Surpass Estimates

Masimo (MASI) delivered earnings and revenue surprises of 8.70% and 2.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

What Makes Helius Medical Technologies, Inc. (HSDT) a New Buy Stock

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Helius Medical Technologies, Inc. (HSDT) Upgraded to Buy: Here's Why

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Tops Revenue Estimates

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -14.86% and 37.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for August 20th

ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.

Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Lags Revenue Estimates

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -68.63% and -21.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Helius Medical Technologies, Inc. (HSDT) Report Negative Earnings Next Week? What You Should Know

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 33.33% and 33.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Misses Revenue Estimates

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 0.00% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?